Hello Bio. Inc. 304 Wall St., Princeton, NJ 08540 USA

T. 609-683-7500 F. 609-228-4994

customercare-usa@hellobio.com



# DATASHEET

LUF7982

### **Product overview**

Name LUF7982 Cat No HB9905

**Biological description** Novel, selective A<sub>2B</sub> covalent ligand (apparent pK<sub>1</sub> values at A<sub>2B</sub>ARs are 8.10 and 9.17 (after 4h),

where a K<sub>i</sub> shift indicates a covalent mode of action). Displays ~100 -fold selectivity for A<sub>2B</sub> compared to A<sub>1</sub>, A<sub>2A</sub> and A<sub>3</sub> receptors. LUF7982 covalently targets lysine residue(s) on the receptor and binds persistently in radioligand displacement and wash-out assays. LUF7982 allows for novel ways to

interrogate the A<sub>2B</sub>AR.

Sold under license from the Oncode Institute and Universiteit Leiden

**Biological action** Other **Purity** >95%

Description Novel Selective A<sub>2B</sub> covalent ligand. Binds irreversibly.

## **Solubility & Handling**

Storage instructions

Solubility overview Soluble in DMSO

Storage of solutions Prepare and use solutions on the same day if possible. Store solutions at -20 °C for up to one month if

storage is required. Equilibrate to RT and ensure the solution is precipitate free before use.

Stable for ambient temperature shipping. Follow storage instructions on receipt. **Shipping Conditions** 

**Important** This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not

for human or veterinary use

### **Chemical Data**

**Chemical name Molecular Weight Chemical structure**  4-(2,6-dioxo-1-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)benzenesulfonyl fluoride

352.3

Molecular Formula

C<sub>14</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>4</sub>S **SMILES** 

InChiKey

CCCN1C(=O)NC2=C(NC(=N2)C2=CC=C(C=C2)S(F)(=O)=O)C1=O

LDROORXQLOXQKW-UHFFFAOYSA-N

Licensing details Sold under license from the Oncode Cancer Institute and Universiteit Leiden

#### References

Development of subtype-selective covalent ligands for the adenosine A(2B) receptor by tuning the reactive group.

Beerkens BLH et al (2022) RSC medicinal chemistry 13

**PubMedID** 35923720